ReviewJournal of oral & maxillofacial research
The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review.
Review in Journal of oral & maxillofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Single-DoseToxins · 2025Trial
- Review
- Review
- Pathophysiology and Management of Refractory Trigeminal Neuralgia.Current neurology and neuroscience reports · 2024Review
- Article
- Modern Approaches to the Treatment of Acute Facial Pain.Current pain and headache reports · 2024Review
- Review
- Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.Toxins · 2024Review
- Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications.Toxins · 2024Review
- Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review.Biomedicines · 2023Review
- Non-Surgical Treatments of Trigeminal Neuralgia from the Perspective of a Pain Physician: A Narrative Review.Biomedicines · 2023Review
- Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases.Dentistry journal · 2022Article
- Review
- The Molecular Basis and Pathophysiology of Trigeminal Neuralgia.International journal of molecular sciences · 2022Review
- Persistent idiopathic facial pain treated with botulinum toxin and pulsed radiofrequency of infraorbital nerve: a case report.Journal of dental anesthesia and pain medicine · 2022Article
- Transient Receptor Potential (TRP) Ion Channels in Orofacial Pain.Molecular neurobiology · 2021Review
- Botulinum Toxin in the Treatment of Headache.Toxins · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe purpose of this article is to systematically review the use, efficacy, differences between botulinum toxin type A doses and side effects of botulinum toxin type A therapy in patients with trigeminal neuralgia. MATERIAL AND
methodsThe search for the performed reviews was done in PubMed and Cochrane library in English language from January 2010 up to February 2020. Inclusion criteria: full-text studies in English language, in which visual assessment scale (VAS) was present, in which patients with trigeminal neuralgia (TN) were participated and the comparison between botulinum toxin type A (BT-A) and saline was done.
resultsThe review included 4 randomized, double-blind, placebo-controlled trials with 8 to 12 weeks follow-up to observe changes in VAS and in frequency of TN attacks, differences between dosages of BT-A in therapy and side effects. Mean VAS of BT-A group decreased by approximately 68% and of palcebo group decreased by approximately 21.6% after the therapy. Mean frequency of TN attacks in 3 studies of BT-A group decreased by 85%, while in palcebo by only 15.9%.
conclusionsBotulinum toxin type A injection therapy is a safe and effective method in management of trigeminal neuralgia. No differences between dosages of botulinum toxin type A were found. Maximum efficacy was noticed between 6 weeks and 3 months after the procedure. Side effects were mostly facial asymmetry after injection, headaches, haematoma, which disappeared in one week.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.